$126 Mln
$-298 Mln
--
As on 28-Sep-2023 16:00 EDT
$-0.12
•
-6.12%
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Kodiak Sciences (KOD)
| -74.30 | -22.36 | -72.78 | -75.82 | -68.40 | -- | -- |
|
S&P BSE Sensex*
| 8.20 | 1.28 | 2.99 | 16.31 | 20.12 | 12.69 | 12.81 |
|
S&P Small-Cap 600#
| -0.98 | -4.98 | -4.11 | 4.69 | 10.13 | 1.54 | 6.57 |
|
2022
|
2021
|
2020
|
2019
|
|
|---|---|---|---|---|
|
Kodiak Sciences (KOD)
| -91.55 | -42.29 | 104.18 | 913.38 |
|
S&P Small-Cap 600
| -17.42 | 25.27 | 9.57 | 20.86 |
|
S&P BSE Sensex
| 4.44 | 21.99 | 15.75 | 14.38 |
|
Stock
|
Peer Median
|
||
|---|---|---|---|
Please wait... |
|||
|
Stock
|
Peer Median
|
||
|---|---|---|---|
Please wait... |
|||
The total asset value of Kodiak Sciences Inc (KOD) stood at $ 664 Mln as on 30-Jun-23
The share price of Kodiak Sciences Inc (KOD) is $1.840000 (NASDAQ) as of 28-Sep-2023 16:00 EDT. Kodiak Sciences Inc (KOD) has given a return of -68.4% in the last 3 years.
Kodiak Sciences Inc (KOD) has a market capitalisation of $ 126 Mln as on 22-Sep-2023. As per Value Research classification, it is a Small Cap company.
The P/B ratio of Kodiak Sciences Inc (KOD) is 0.80 times as on 22-Sep-2023, a -0.69% premium to its peers’ median range of 2.54 times.
Since, TTM earnings of Kodiak Sciences Inc (KOD) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Kodiak Sciences Inc (KOD) and enter the required number of quantities and click on buy to purchase the shares of Kodiak Sciences Inc (KOD).
Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy. The company's preclinical stage product candidate includes KSI-501, a bispecific conjugate to treat retinal diseases with an inflammatory component; and KSI-601, a triplet biopolymer conjugate for the treatment of dry AMD. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California.
The CEO & director of Dr. Victor Perlroth M.D.. is Kodiak Sciences Inc (KOD), and CFO & Sr. VP is Mr. John A. Borgeson CPA, M.B.A., MBA, CPA.
The promoters of Kodiak Sciences Inc (KOD) have pledged 0% of the total equity as on Jun-23.
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
523
|
|
|
498
|
|
|
497
|
|
|
392
|
| Kodiak Sciences Inc (KOD) | Ratios |
|---|---|
|
Return on equity(%)
|
--
|
|
Return on capital employed(%)
|
--
|
|
Debt-to-equity ratio
|
0
|
|
Dividend yield(%)
|
0
|
No, TTM profit after tax of Kodiak Sciences Inc (KOD) was $-298 Mln.
$125.89 Mln
$0.00 Mln
$-298.45 Mln
$378.67 Mln
$84.79 Mln
High
$1.82 - 9.79
52,453,200
NASDAQ: KOD
Palo Alto, CA
https://kodiak.com
Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor... antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy. The company's preclinical stage product candidate includes KSI-501, a bispecific conjugate to treat retinal diseases with an inflammatory component; and KSI-601, a triplet biopolymer conjugate for the treatment of dry AMD. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California. Read more
Learn the principles, mindset and tools you need to become a successful Mutual Fund and Stock investor from the masters who have been doing this for decades.
Use India's most advanced investment tracker to track, analyse and get updates and insights on your investments.
Get an analysis of your portfolio along with actionable, general tips and insights, guidance on where to invest based on your goals, and experts' opinions on individual Mutual Funds and Stocks.
Value Research offers the most advanced and detailed data & analytics available on Mutual Funds and Stocks. Sign up and unlock the power yourself.
Unlimited access to advice from India's top experts
The most comprehensive analysis of funds and stocks in India
A holistic portfolio manager to help track all your investments easily
And much more, like guides, tools, webinars, videos and eBooks.
Share via Facebook 
Share via Twitter 
Share via LinkedIn 
Share this
